5 Drugs Stocks Dragging The Industry Down

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.1%) at 15,256 as of Monday, June 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,353 issues advancing vs. 1,578 declining with 107 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Dynavax Technologies Corporation ( DVAX), down 35.43, and Alexion Pharmaceuticals ( ALXN), down 1.66. A company within the industry that increased today was Novo Nordisk A/S ( NVO), up 0.59.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Vertex Pharmaceuticals is down $0.81 (-1.0%) to $82.00 on light volume Thus far, 591,687 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $81.20-$82.90 after having opened the day at $82.66 as compared to the previous trading day's close of $82.81.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.3 billion and is part of the health care sector. Shares are up 86.2% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants